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Abstract Many pre-transplant factors are known to influ-
ence the outcome of allogeneic stem cell transplantation
(SCT) treatment in myelodysplastic syndromes (MDS).
However, patient cohorts are often heterogeneous by dis-
ease stage and treatment modalities, which complicates
interpretation of the results. This study aimed to obtain a
homogeneous patient cohort by including only de novo
MDS patients who received upfront allogeneic SCT after
standard high dose myelo-ablative conditioning. The effect
of pre-transplant factors such as age, disease stage,
transfusions, iron parameters and comorbidity on overall
survival (OS), non-relapse mortality (NRM), and relapse
incidence (RI) was evaluated in 201 patients. In this
cohort, characterized by low comorbidity and a short inter-
val between diagnosis and transplantation, NRM was the
most determinant factor for survival after SCT (47 % after
2-year follow-up). WHO classification and transfusion
burden were the only modalities with a significant impact
on overall survival after SCT. Estimated hazard ratios (HR)
showed a strongly increased risk of death, NRM and RI, in
patients with a high transfusion-burden (HR 1.99;
P = 0.006, HR of 1.89; P = 0.03 and HR 2.67; P = 0.03).
The HR’s for ferritin level and comorbidity were not
significantly increased.
Keywords Myelodysplastic syndromes . Red blood cell
transfusion . Iron overload . Allogeneic hematopoietic stem
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Introduction
Myelodysplastic syndromes (MDS) are a heterogeneous
group of myeloid bone marrow disorders characterized by
clonal hematopoiesis, impaired differentiation, peripheral
cytopenias, and an increased risk of progression to acute
myeloid leukemia (AML) [1]. Allogeneic hematopoietic stem
cell transplantation (SCT) is considered the only modality
with proven curative potential, but leads to considerable
treatment-related morbidity, mortality, and decreased quality
of life [2–5].
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Most MDS patients receive red blood cell (RBC) transfu-
sions during the course of their disease [6]. Transfused
patients are prone to long-term accumulation of iron due to
red blood cell (RBC) transfusions as well as susceptible to
direct iron toxicity due to the formation of reactive oxygen
species (ROS) [7]. Iron accumulation in MDS may start be-
fore patients become transfusion-dependent because of inef-
fective erythropoiesis, which blocks hepcidin production and
subsequently increases iron absorption from the gut.
Myelosuppressive therapy blocks erythropoiesis immediately
and may result in direct iron toxicity [8]. Elevated toxic iron
radicals may lead to an increased risk of infections, higher
SCT mortality, leukemic transformation, and tissue damage
[9–11]. Many studies described the negative impact of
transfusion-dependency and associated iron accumulation on
treatment outcome after SCT. Serum ferritin has often been
used as a surrogate marker for iron overload. It is associated
with an adverse effect on overall survival (OS), non-relapse
mortality (NRM), and relapse incidence (RI) [4, 12–15].
However, ferritin levels are also associated with advanced
stages of MDS, number of prior regimens and infections
[16]. Therefore, pre-transplant ferritin levels are less suited
to evaluate iron toxicity caused by transfusions and ineffective
erythropoiesis in MDS.
High dose chemotherapy decreases erythropoiesis and uti-
lization of iron, which leads to an increased iron load [17].
High dose myeloablative preparative regimens cause more
serious organ toxicity, higher risk of infections and acute
graft-versus-host disease (GvHD) than non-myeloablative
regimens [18]. Therefore, this study aimed to analyze a homo-
geneous group of MDS patients only treated with high dose
chemotherapy as part of the transplant conditioning, without
previous anti-leukemic treatment (to minimize comorbidity).
This allows more insight in the role of transfusion-burden and
associated iron accumulation during SCT procedures. Insight
in factors contributing to NRM may lead to better treatment
approaches in patients who are to be treated with SCT.
Patients and methods
The Chronic Malignancies Working Party (CMWP) of the
European Group of Blood and Marrow Transplantation
(EBMT) collected retrospective data of adult patients with
proven MDS according to the WHO classification, who re-
ceived allogeneic SCT after high dose conditioning. Centers
who had transplanted more than 4 MDS patients between
2000 and 2005 were invited to participate in this survey.
Due to strict inclusion criteria 34 centers were selected to
participate; leading to a cohort of 243 patients (range: 1 to
19 per center). The data were checked on diagnosis, primary
origin, and previous treatment with intensive chemotherapy.
With this procedure, 24 patients were excluded because of
secondary origin, 18 patients because of missing relevant
transplantation data. The additional survey collected data
which are not routinely recorded in the EBMTregistry, includ-
ing ferritin levels, serum iron levels, transferrin saturation and
number of RBC-transfusions. Patients’ health status, includ-
ing co-morbidities, was recorded through follow-up forms up
to 5 years post-transplant. All clinical variables were mea-
sured at time of transplantation in patients undergoing upfront
SCT, without other pre-transplant anti-leukemic treatment.
Patients were analyzed according to patient and donor
characteristics, WHO classification, number of RBC units
transfused, presence of comorbidity, iron parameters includ-
ing ferritin, transferrin and plasma iron, and cytogenetic risk
category according to the International Prognostic Scoring
System (IPSS) risk categories [5, 19]. Patients were diagnosed
and classified prior to the introduction of the revised IPSS,
therefore the IPSS was applied. Data on extra-hematologic
comorbidities that can influence the outcome of treatment
were calculated using the Sorror co-morbidity index [18].
The procedures were in accordance with the ethical standards
with the Declaration of Helsinki.
End points and statistical analysis
Primary end-points were OS, NRM, and RI. OS was defined
as the probability of survival since transplantation; death from
any cause was considered as an event. Patients alive at time of
last follow-up were censored at this date. NRMwas defined as
the probability of any death in the absence of relapse since
SCT. RI was defined as the probability of hematologic relapse
(definition: cytological and/or histological evidence of the dis-
ease in the marrow-blood and/or in extramedullary sites after
SCT). For NRM and RI, patients were censored if relapse free
and alive at time of last follow-up.
The probabilities of OS were estimated using the Kaplan-
Meier product limit method. Estimates of NRM and RI were
calculated using cumulative incidence curves to accommodate
competing risks (relapse, considered a competing risk for
NRM and vice versa). Univariate comparisons were based
on the Kaplan-Meier method for OS and on non-parametric
cumulative incidence curves for RI and NRM. All signifi-
cance tests are Cox-model based score tests (corresponding
to the usual log-rank tests for OS and NRM).
Cox proportional hazards regression was used to assess the
impact of potential prognostic factors in multivariate analyses.
The impact of these factors on OS, NRM, and RI was modeled
by means of cause-specific hazards. For each outcome, we
created three models. The first model contained baseline
(expected) predictive factors: WHO classification, age, donor
type, sex-match (a female donor-male recipient combination
has been described as a negative influence on SCT outcome)
[20], time between diagnosis and SCT and cytogenetic
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abnormalities (model 1; see Table 2) [6, 21]. Then, we added
RBC-transfusions, and comorbidity, respectively (models 2–3).
We checked the impact of missing values for the key
variables RBC transfusions and comorbidity score on the out-
comes both in the univariate and in the multivariate analyses.
Since we concluded that the estimates of the coefficients of
interest were not influenced significantly by the presence or
absence of the patients with missing values for each of these
key variables in turn, we presented the results based on differ-
ent subsets of our data set with non-missing information.
Analyses were performed using PASW Statistics version
18.0 (SPSS, Chicago, IL). Cumulative incidences were
calculated by means of SPSS macros developed by the
Department of Medical Statistics and Bioinformatics of the
Leiden University Medical Center (Leiden, the Netherlands);
they are based on the hazard estimates from the Cox models.
All P values are two-sided and P < 0.05 was considered sig-
nificant. The dataset for analysis was closed in March 2011.
Results
A total of 201 patients underwent allogeneic SCT after high
dose conditioning for untreatedMDS between 2001 and 2005.
Table 1 describes patients’ characteristics. The median age
was 49 years (range 18–70) and 119 patients were male.
Due to the selection criteria of upfront SCT without prior
treatment, the group of patients with refractory anemia (RA),
refractory anemia with ringed sideroblasts (RARS) or isolated
deletion of the 5q chromosome (5q-) population was relatively
large (36 %) in comparison to other reports 1. It is important to
realize that this study was conducted prior to the introduction of
lenalidomide and hypo-methylating agents. Treatment
regiments were high dose myeloablative regimens, most
commonly based on Busulfan (N = 82), Treosulfan (N = 15)
and Melfalan (N = 15) or total body irradiation (TBI; N = 62)
in dosages used in myelo-ablative schedules [22, 23]. GvHD
prophylaxis regimens comprised of Cyclosporin (N = 159),
methotrexate (N = 107), mycophenolate mofetil (N = 24) and/
or ATG (N = 65). Median time between diagnosis and SCT
was 8 months. Pre-SCT comorbidity was present in 34 % of
the patients. Of the patients transfused, 23% received >20 RBC
units. Mean pre-transplant iron parameters were ferritin
1288 ng/mL (N = 62; range 72–9695), transferrin 233 mg/dL
(N = 30; range 56–538), transferrin saturation 29 % (N = 23;
range 7–160), serum iron 171 μg/dL (N = 43; range 30–467).
Six patients received iron chelation post-SCT. The Sorror comor-
bidity index (HCT-CI) subdivided patients in Bno comorbidity^
(HCT-CI: 0) 66 %, Bmild/moderate comorbidity^ (HCT-
CI of 1-2) 25%, or Bsevere comorbidity^ (HCT-CI of ≥3) 9%.
The OS, NRM, and RI at 2 years post-SCT were 47, 41,
and 14%, respectively. Figure 1 illustrates the OS stratified for
WHO classification, RBC transfusions, ferritin level, and
comorbidity. In univariate analyses, WHO classification
significantly affected OS (P = 0.04) and RI (P = 0.003), but
did not affect NRM (P = 0.38). Age, cytogenetics, donor type,
match sex recipient-donor, and time between diagnosis and
SCT did not have a significant impact on OS, NRM, and RI
in univariate analyses (data not shown).
Treatment outcome according to transfusion-burden
To examine the influence of transfusion-burden, patients were
subdivided into two groups depending on the amount of RBC
units received pre-SCT, ≤20 and >20 RBC transfusions.
Patients with a low transfusion burden had a significantly
(P = 0.006) higher 2-year OS than patients with a high
transfusion-burden (52 % versus 31 %), which was mainly
explained by a higher NRM for patients with >20 RBC trans-
fusions. The 2-year NRM was different in both groups: 54 %
for patients with >20 RBC-transfusions, compared to 36% for
the patients with less RBC transfusions (P = 0.02). The RI was
comparable in both groups: 17 and 15 % at 2 years (P = 0.20).
Treatment outcome according to ferritin levels
Ferritin levels prior to transplantation were reported in a
minority of patients (N = 62). Based on ferritin levels, patients
were subdivided into two categories: <1000 ng/ml (N = 35)
and ≥1000 ng/ml (N = 27). Patients with a higher ferritin level
had a 14 % lower 2-year survival than patients with a normal
ferritin level (37 versus 51 %; Fig. 1) (P = 0.23). The 2-year
NRM and RI were 44 and 19%, in patients with a ferritin level
≥1000 ng/ml, compared to 43 and 9 %, in patients with a
ferritin level below 1000 ng/ml. The differences between the
RI of both groups were not significant.
Treatment outcome according to comorbidity
Since the number of patients with comorbidities was too small
to subdivide the patients according to Sorror comorbidity
index, presence and absence of comorbidities were used.
The Kaplan Meier curves showed a 10 % decrease in 2-year
survival for the patients with comorbidity (40 versus 50 %).
However, the difference in OS was not significant (P = 0.15).
RI was equal in both groups (16 vs 14 %; P = 0.63). NRM for
patients with a comorbidity was 48 %, compared to 37 % for
patients without comorbidity (P = 0.12).
Multivariate analysis of pre-transplant factors
Cox models were built for the multivariate analysis (see
Patients and methods). The baseline model, which included
expected prognostic factors showed that transplantation with
an unrelated donor had a very significant impact on the HR for
RI (HR 0.28; P = 0.002) but no influence on survival (HR
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1.03;P = 0.89) (Table 2). Although other studies used 40 years
of age as a cut-off point, we decided to use 50 years since this
was closer to the median 2. Poor risk cytogenetic abnormali-
ties (≥3 abnormalities or an abnormal chromosome 7) had a
significant impact on the HR for RI (HR 3.01; P = 0.009). This
did not influence survival significantly (HR 1.31; P = 0.29).
WHO classification influenced the outcome significantly
(Table 2). In comparison to RA/RARS patients, patients with
a refractory cytopenia with multilineage dysplasia (RCMD)
had a statistically decreased survival (HR 3.12; P = 0.001)
and high HR for NRM (HR 2.80; P = 0.006). This impact
remained significantly increased in all models. In comparison
to RA/RARS patients, patients with a refractory anemia with
excess blast-1 (RAEB-1) and patients with MDS transformed
into AML (MDS/AML) had a significantly higher risk of
relapse, HR 5.95 (P = 0.001), and HR 5.66 (P = 0.003), respec-
tively, leading only to a significantly decreased survival in
MDS/AML patients (HR1.85; P = 0.03).
Age, sex match donor-recipient, and interval between
diagnosis and transplantation had no significant prognostic
impact on OS, NRM, and RI in the baseline model (Table 2).
The Cox models built for transfusion-burden showed that a
high transfusion-burden resulted in an inferior outcome for
OS, NRM, and RI, with a HR of 1.99 (P = 0.006), 1.89
(P = 0.03), and 2.67 (P = 0.03) respectively (model 2). The
presence of comorbidity was associated with a non-
significant increased risk of death (1.43; P = 0.15) and NRM
(HR 1.67; P = 0.08) but no impact on RI (HR 0.71; P = 0.44)
(Table 2; model 3).
Discussion
Several studies addressed the impact of transfusion-dependen-
cy, transfusion-burden and iron overload/toxicity after
transplantation in MDS patients. However, data from these
Table 1 Baseline characteristics
at time of transplantation of all
patients in the study
Total
(n = 201)
≤20 RBC units
(n = 86)
>20 RBC units
(n = 41)
P value*
Median age (range) (n = 201) 49 (18–70)
≤50 years 103 (51 %) 43 (50 %) 17 (41 %) 0.37
>50 years 98 (49 %) 43 (50 %) 24 (59 %)
Sex (male) 119 (59 %) 52 (61 %) 24 (59 %) 0.84
WHO classification (n=201)
RA/RARS/5q- 72 (36 %) 26 (30 %) 14 (34 %) 0.90**
RCMD 15 (8 %) 3 (4 %) 2 (5 %)
RAEB-1 34 (17 %) 20 (23 %) 5 (12 %)
RAEB-2 39 (19 %) 18 (21 %) 11 (27 %)
MDS/AML 41 (20 %) 19 (22 %) 9 (22 %)
Cytogenetics (n = 152)***
Good 67 (44 %) 32 (41 %) 17 (47 %) 0.64
Intermediate 43 (28 %) 24 (31 %) 8 (22 %)
Poor 42 (28 %) 22 (28 %) 11 (31 %)
Median time Dx-Tx 8 (0.3–
274)
≤6 months 80 (40 %) 40 (47 %) 11 (27 %) 0.03
>6 months 121 (60 %) 46 (53 %) 30 (73 %)
Donor type (n = 199)
Sibling 110 (55 %) 42 (49 %) 18 (45 %) 0.65
Unrelated donor 89 (45 %) 43 (51 %) 22 (55 %)
Match sex recipients-donor (n = 201)
Male-female 46 (23 %) 19 (22 %) 8 (20 %) 0.74
Other 155 (77 %) 67 (78 %) 33 (80 %)
Comorbidity (n = 145)
No 95 (66 %) 54 (63 %) 28 (68 %) 0.54
Yes 50 (34 %) 32 (37 %) 13 (32 %)
Univariate comparisons between baseline characteristics of patients who received ≤20 RBC units and those who
received >20 RBC units. (*) P values are derived from the chi-square test or Cochran-Armitage test for trend (**).
According to IPSS risk categories (***)
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retrospective studies should be interpreted carefully because
patient cohorts are often heterogeneous with regards to disease
status, comorbidity, and treatment modalities [19, 24]. High
risk patients frequently receive cytoreductive therapy (inten-
sive chemotherapy or hypomethylating agents) prior to the
transplant conditioning, sometimes as part of bridging. The
value of cytoreductive strategies is not supported by retrospec-
tive [25] and prospective studies. We have chosen this
homogeneous population with a relative low relapse risk after
transplantation and a long median follow-up of 5 years. Both
in AML and in MDS, ferritin levels had a pronounced influ-
ence on OS in heavily pretreated patients [12, 16]. Since
ferritin is an acute phase reactant, we postulate that elevated
ferritin levels are heavily influenced by stage of disease and by
recently applied intensive chemotherapy and associated
invasive infections. Therefore, the homogeneity of this cohort
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Fig. 1 Overall survival stratified forWHO classification (a), transfusion burden (b), iron load (c), and comorbidity (d) (Kaplan-Meier curves). P values
are based on the two-sided log-rank test
may provide more insight in the impact of relevant prognostic
factors in the setting of SCT. In addition, we focused on
obtaining a complete pre-transplantation transfusion history
to be able to accurately analyze the impact of transfusion
burden rather than using ferritin levels as surrogate marker.
In this study, NRM was the most determinant factor for
survival post-SCT, probably due to the large number of pa-
tients with <5 % blasts (36 %). The favorable OS of the large
RA/RARS groupmay explain the lack of prognostic impact of
several putative prognostic factors, including age, sex-match
donor-recipient, time between diagnosis and SCTand cytoge-
netic abnormalities [19]. Cytogenetic abnormalities did have
an impact on RI, but not on OS since NRM was the driving
force of death in this study. In all models, age had no impact
on outcome. The low incidence of comorbidities may explain
the loss of the prognostic impact by age in this patient cohort.
As expected, WHO classification had a major impact on out-
come (P = 0.04). In comparison to RA/RARS patients,
RCMD patients showed a significantly decreased survival
(HR 3.12; P = 0.001). The HR’s of RCMD for OS and NRM
remained significantly increased after adding transfusion-
burden and comorbidities to the models. The increase of the
HR after adding number of transfusions and comorbidity
suggests that the impaired survival is intrinsic to this MDS
category. However, this unique observation needs confirmation
by additional studies. As expected, RAEB-1 and MDS/AML
patients had a significantly higher risk on RI, 5.95; P = 0.001,
and HR 5.66; P = 0.003, compared to RA/RARS patients, lead-
ing to a significantly decreased survival in MDS/AML patients
(HR 1.85; P = 0.03).
Transfusion dependency appeared to have a major prog-
nostic impact on outcome. Multivariate analysis showed a
significantly decreased OS in patients who received >20
RBC transfusions prior to conditioning (HR 1.99; P =
0.006), due to an increased NRM and RI with a HR of 1.89
(P = 0.03) and HR 2.67 (P = 0.03) respectively. A higher
transfusion-dependency may indicate a more pronounced
marrow failure which may be associated with a decreased
survival. In addition, toxicity caused by RBC transfusions
might be deleterious either because of increasing iron load
or because of other adverse effects, e.g., transfusion-related
immunomodulation (TRIM) and the effect of stored blood
on the microcirculation hemodynamics and tissue oxygena-
tion [26, 27]. A more challenging explanation is given by
Hod et al. [28]. They described that RBC transfusions with
stored blood give a sudden rise in non-transferrin bound iron
Table 2 Multivariate analysis for
overall survival, non-relapse
mortality, and relapse incidence
with traditional patient, disease
and transplantation-related
variables (model 1) extended with
RBC-transfusions (model 2), and
comorbidity (model 3),
respectively
Overall
survival
Non-relapse
mortality
Relapse
incidence
HR p value HR p value HR p value
Model 1 (n = 199)
Donor type (HLA matched unrelated* vs sibling) 1.03 0.89 1.20 0.43 0.28 0.002
Cytogenetic abnormalities** 0.54 0.91 0.02
Good and intermediate 1 1 1
Poor 1.31 0.29 0.98 0.94 3.01 0.009
Time Dx-Tx (>6 vs ≤6 months) 1.31 0.20 1.33 0.24 1.26 0.54
WHO classification 0.01 .03 0.006
RA/RARS 1 1 1
RCMD 3.12 0.001 2.80 0.006 3.58 0.15
RAEB-1 1.15 0.65 0.77 0.48 5.95 0.001
RAEB-2 1.57 0.13 1.41 0.29 1.81 0.35
MDS/AML 1.85 0.03 1.40 0.28 5.66 0.003
Age (≤50 vs >50 years) 1.28 0.24 1.12 0.64 1.85 0.10
Sex-match donor-recipient (m-f vs other) 1.05 0.84 0.99 0.98 1.11 0.80
Model 2 (n = 125)
RBC-transfusion (>20 RBS-units vs ≤20 RBC-units) 1.99 0.006 1.89 0.027 2.67 0.031
Model 3 (n = 143)
Comorbidity (yes vs no) 1.43 0.15 1.67 0.08 0.71 0.44
Cox regression models for the (cause-specific) hazards were fitted on different restricted datasets with full
information on the main variables of interest. The entries in the table are hazard ratios and their associated p values
and group size. HRs (with their p values) in italics have a statistically significant impact on OS, NRM, or RI, at the
5 %-level. (*) Mismatched siblings and mismatched unrelated donors are included in the HLAmatched unrelated
donor category. (**) patients with missing information for this variable were kept in the analysis with variable
level Bmissing^ (HRs not shown)
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(NTBI), due to a rapid clearance of the damaged blood cells.
This sudden increase in NTBI may enhance transfusion-
related complications [9, 10]. To minimize transfusions toxic-
ity, they advised to use fresh erythrocytes for transfusions,
which will have a major impact on the logistics of clinical
practice. Iron chelating therapy before and after SCT might
be a good alternative. Chelation therapy may improve hemo-
globin levels and reduce transfusion requirement in a minority
of patients with MDS [29]. Reduction of the interval between
diagnosis and transplantation minimizes the exposure time to
ineffective erythropoiesis, transfusion-dependent period and
the number of transfusions. Comorbidity in this studied pop-
ulation was limited, which may explain the absent prognostic
impact in contrast to other studies 3. A prospective non-
interventional study within the CMWP of the EBMT, to look
at the influence of iron toxicity and transfusions on treatment
outcome after allogeneic SCT in MDS patients has been com-
pleted and the analysis of the data is ongoing.
In summary, in this homogeneous patient cohort, NRM
was the most determinant factor for survival after SCT.
WHO classification and transfusion-burden were the only
pre-transplant factors with a significant impact on survival.
Cytogenetic abnormalities had only a significant influence
on the HRs for RI. More research on the influence and path-
ophysiology of transfusion toxicity is mandatory in particular
the role of iron chelation before SCTand phlebotomies and/or
iron chelation after SCT.
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